Evidence map›Paper›PMID 36383784›Full record

ArticleMemorias do Instituto Oswaldo Cruz2022

Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.

Perpétua do Socorro Silva Costa, Miriãn Ferrão Maciel-Fiuza, Thayne Woycinck Kowalski, Lucas Rosa Fraga, Mariléa Furtado Feira, Luís Marcelo Aranha Camargo, Daniele Iop de Oliveira Caldoncelli, Maria Irismar da Silva Silveira, Lavínia Schuler-Faccini, Fernanda Sales Luiz Vianna

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Memorias do Instituto Oswaldo Cruz, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Perpétua do Socorro Silva CostaUniversidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Genética e Biologia Molecular, Porto Alegre, RS, Brasil.
Miriãn Ferrão Maciel-FiuzaUniversidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Genética e Biologia Molecular, Porto Alegre, RS, Brasil.
Thayne Woycinck KowalskiUniversidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Genética e Biologia Molecular, Porto Alegre, RS, Brasil.
Lucas Rosa FragaHospital de Clínicas de Porto Alegre, Centro de Pesquisa Experimental, Laboratório de Medicina Genômica, Porto Alegre, RS, Brasil.
Mariléa Furtado FeiraUniversidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Genética e Biologia Molecular, Porto Alegre, RS, Brasil.
Luís Marcelo Aranha CamargoUniversidade de São Paulo, Instituto de Ciências Biomédicas-5, Monte Negro, RO, Brasil.
Daniele Iop de Oliveira CaldoncelliCentro de Referência Nacional em Dermatologia Sanitária Dona Libânia, Fortaleza, CE, Brasil.
Maria Irismar da Silva SilveiraCentro de Referência Nacional em Dermatologia Sanitária Dona Libânia, Fortaleza, CE, Brasil.
Lavínia Schuler-FacciniUniversidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Genética e Biologia Molecular, Porto Alegre, RS, Brasil.
Fernanda Sales Luiz ViannaUniversidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Genética e Biologia Molecular, Porto Alegre, RS, Brasil.ORCID http://orcid.org/0000-0001-6339-4869
Universidade Federal do Rio Grande do Sul · BRInstituto de Dermatologia Dona Libania · BRCentro Universitário São Lucas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErythema nodosum leprosum (ENL) is an acute and systemic inflammatory reaction of leprosy characterised by painful nodules and involvement of various organs. Thalidomide is an immunomodulatory and anti-inflammatory drug currently used to treat this condition. Cereblon (CRBN) protein is the primary target of thalidomide, and it has been pointed out as necessary for the efficacy of this drug in others therapeutics settings.

objectivesIn this study, we aimed to evaluate the influence of CRBN gene variants on the dose of thalidomide as well as its adverse effects during treatment of ENL.

methodsA total of 103 ENL patients in treatment with thalidomide were included in this study. DNA samples were obtained from saliva and molecular analysis of CRBN gene were performed to investigate the variants rs1620675, rs1672770 and rs4183. Different genotypes of CRBN variants were evaluated in relation to their influence on the dose of thalidomide and on the occurrence of adverse effects.

findingsNo association was found between CRBN variants and thalidomide dose variation. However, the genotypes of rs1672770 showed association with gastrointestinal effects (p = 0.040). Moreover, the haplotype DEL/C/T (rs4183/rs1672770/rs1620675) was also associated with gastrointestinal adverse effects (p = 0.015). MAIN

conclusionsOur results show that CRBN variants affect the treatment of ENH with thalidomide, especially on the adverse effects related to the drug.

Indexed as

Erythema NodosumLeprosy, LepromatousLeprosy, MultibacillaryHumansLeprostatic AgentsThalidomideLeprostatic AgentsThalidomide

Identifiers

PMID36383784
PMCPMC9668341
OpenAlexW4309436496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.